(Q33795864)

29 July 2017

1 reference

title

Efficacy and adverse effects of medications used in the treatment of glaucoma (English)

1 reference

29 July 2017

Camras CB

1

1 reference

29 July 2017

Toris CB

series ordinal

2

1 reference

29 July 2017

Tamesis RR

series ordinal

3

1 reference

29 July 2017

publication date

1 November 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

15

1 reference

29 July 2017

issue

5

1 reference

29 July 2017

page(s)

377-388

1 reference

A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group.

29 July 2017

cites work

1 reference

12 December 2020

Timolol, dose response and duration of action

1 reference

12 December 2020

Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group.

1 reference

12 December 2020

Apraclonidine hydrochloride: its past, present, and future in the therapy of chronic glaucoma

1 reference

12 December 2020

Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group

1 reference

12 December 2020

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

1 reference

12 December 2020

Improved lung function tests on changing from topical timolol: non-selective beta-blockade impairs lung function tests in elderly patients

1 reference

12 December 2020

How often is medication taken as prescribed? A novel assessment technique

1 reference

12 December 2020

Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor

1 reference

12 December 2020

Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans

1 reference

12 December 2020

Cystoid macular edema associated with the use of latanoprost

1 reference

12 December 2020

The effect of topical clonidine on intraocular pressure

1 reference

12 December 2020

Efficacy and safety of timolol solution once daily versus timolol gel in treating elevated intraocular pressure.

1 reference

12 December 2020

Once-daily versus twice-daily levobunolol (0.5%) therapy. A crossover study.

1 reference

12 December 2020

New Approaches to Antiglaucoma Therapy

1 reference

12 December 2020

Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide

1 reference

12 December 2020

Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans

1 reference

12 December 2020

Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens

1 reference

12 December 2020

A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group

1 reference

12 December 2020

Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2 alpha analogue

1 reference

12 December 2020

A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group

1 reference

12 December 2020

Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation.

1 reference

12 December 2020

CME and anterior uveitis with latanoprost use.

1 reference

12 December 2020

Prostaglandin-induced iris color darkening. An experimental model

1 reference

12 December 2020

Latanoprost twice daily is less effective than once daily: indication of receptor subsensitivity?

1 reference

12 December 2020

CME and anterior uveitis with latanoprost use

1 reference

12 December 2020

Epinephrine maculopathy

1 reference

12 December 2020

A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Dorzolamide Dose-Response Study Group.

1 reference

12 December 2020

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group

1 reference

12 December 2020

Effects on IOP restoration and blood-aqueous barrier after long term treatment with latanoprost in open angle glaucoma and ocular hypertension

1 reference

12 December 2020

The effects of withdrawal of timolol in chronically treated glaucoma patients

1 reference

12 December 2020

Latanoprost and Hyperpigmentation of Eyelashes

1 reference

12 December 2020

Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients

1 reference

12 December 2020

Adverse effects of latanoprost on patients with medically resistant glaucoma

1 reference

12 December 2020

A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group.

1 reference

12 December 2020

Irreversible corneal decompensation in patients treated with topical dorzolamide

1 reference

12 December 2020

The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine

1 reference

12 December 2020

Comparison of quality of life and patient preference of dorzolamide and pilocarpine as adjunctive therapy to timolol in the treatment of glaucoma

1 reference

12 December 2020

Nephrolithiasis with dorzolamide

1 reference

12 December 2020

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

12 December 2020

Cystoid macular edema associated with latanoprost use.

1 reference

12 December 2020

Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes.

1 reference

12 December 2020

The efficacy and safety of dorzolamide as adjunctive therapy to timolol maleate gellan solution in patients with elevated intraocular pressure. Additivity Study Group

1 reference

12 December 2020

The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. The Dorzolamide Additivity Study Group

1 reference

12 December 2020

Apparent central nervous system depression in infants after the use of topical brimonidine

1 reference

12 December 2020

Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, diamox; a preliminary report

1 reference

12 December 2020

A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group

1 reference

12 December 2020

Medical Management of Glaucoma

1 reference

12 December 2020

Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost

1 reference

12 December 2020

Aqueous humor flow in human eyes treated with dorzolamide and different doses of acetazolamide

1 reference

12 December 2020

Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.

1 reference

12 December 2020

Superior cervical ganglionectomy-induced lowering of intraocular pressure in rabbits: role of prostaglandins and neuropeptide Y

1 reference

12 December 2020

Effect of dorzolamide on corneal endothelial function in normal human eyes.

1 reference

12 December 2020

CME and anterior uveitis with latanoprost use.

1 reference

12 December 2020

Ophthalmic beta-blockers since timolol

1 reference

12 December 2020

A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study

1 reference

12 December 2020

Cystoid macular edema associated with topically applied epinephrine in aphakic eyes

1 reference

12 December 2020

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group

1 reference

12 December 2020

Adverse side effects associated with latanoprost.

1 reference

12 December 2020

Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure

1 reference

12 December 2020

A comparison of the ocular hypotensive efficacy of once-daily and twice-daily levobunolol treatment

1 reference

12 December 2020

The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma

1 reference

12 December 2020

Brimonidine tartrate: a one-month dose response study

1 reference

12 December 2020

Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group

1 reference

12 December 2020

Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group

1 reference

12 December 2020

Correlation of Epinephrine Use and Macular Edema in Aphakic Glaucomatous Eyes

1 reference

12 December 2020

Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma

1 reference

12 December 2020

Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension

1 reference

12 December 2020

Central Corneal Thickness in Normal, Glaucomatous, and Ocular Hypertensive Eyes

1 reference

12 December 2020

Latanoprost-associated cystoid macular edema

1 reference

12 December 2020

Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine

1 reference

12 December 2020

Anterior uveitis associated with latanoprost

1 reference

12 December 2020

10.2165/00002512-199915050-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1025848965

0 references

1 reference